Stay updated on Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.

Latest updates to the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check20 days agoChange DetectedThe web page has been updated from version v2.16.1 to v2.16.2.SummaryDifference0.3%
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check42 days agoChange DetectedThe content regarding 'Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)' has been completely removed from the page.SummaryDifference0.3%
- Check63 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check70 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
Stay in the know with updates to Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lorlatinib After First-line TKI Failure in ROS1 NSCLC Clinical Trial page.